Prospective randomized human trials, crossover pharmacokinetic studies, and ClinicalTrials.gov interventional readouts with direct participant sample sizes (N). Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Our primary outcome of diabetes full symptom relief at 24 weeks was not statistically significantly different.
Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type...
Tadalafil once daily represents an effective and well tolerated medical treatment for Asian men presenting with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Our findings highlight the utility of focusing on the dynamic interaction between depressive symptoms to better understand how the treatment with ADs unfolds over time.
Atorvastatin, rosuvastatin, and pitavastatin have a beneficial and safe effect in NAFLD/NASH patients as recorded by the improvement in the NAS (representing NAFLD activity) and FIB-4 (representing liver fibrosis) scores.
Applied to the skin minoxidil 5% solution either alone or in combination with FCO 2 laser could be considered a safe and tolerable method for AA treatment.
Herbal treatment is proven to be clinically effective in most of the patients; particularly PCOs patients with menstrual irregularities.
Hot flushes appear to be no significant determinant for the responses of vascular markers to HT use.
The most common side effects were nasopharyngitis, elevated blood uric acid levels and hyperuricemia, and the latter two events were more frequent in the T80/A5/H12.5 group than in the T80/A5 group.
Two individuals complained of impotence, which disappeared within a few days of discontinuation of applied to the skin minoxidil.
Adding EZE to ATV single-drug treatment represents an attractive and well-tolerated treatment option to bring patients at high risk of CHD to the aggressive LDL-C goals recommended by recent treatment guidelines.
Hot flushes modify the HT-mediated responses in ambulatory BP.
Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain full symptom relief during 16 weeks of continuation treatment.
Two common HT regimens differentially alter pituitary-ovarian hormone levels, altering feedback cycles and interhormonal associations in recently menopausal women.
A total of 146 patients were enrolled and the demographic characteristics were similar among the 3 treatment groups.
Pairwise comparisons showed that both intervention groups were superior to the CG on all motor skill outcomes (all p < 0.05), with no statistically significant differences between EG1 and EG2.
Augmentation of sertraline with 2 g/d of EPA for 10 weeks did not result in greater improvement in depressive symptoms compared to sertraline and corn oil placebo in patients with depression and CHD or CHD risk factors.
Women treated with E2/P4 had a greater response to treatment with more VMS-free days than with placebo.
To our knowledge, this is the first trial to evaluate a brief, self-guided, culturally adapted digital mindfulness intervention as an add-on booster to pharmacotherapy in Chinese adults with GAD.
Over 102 weeks, dapagliflozin improved glycaemic control, and reduced weight and fat mass, without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin.
AR CAG affected the response of some variables to TRT in the TIMES2 study, although the association with HOMA-IR did not reach significance.
Finasteride treatment was generally well tolerated.
Compared with atorvastatin, rosuvastatin produced greater reductions in LDL-C, which may offer advantages in LDL-C goal attainment over existing lipid-lowering therapies.
Early combination of EZ with AS, rather than a stepwise approach, significantly reduced LDL-C levels and improved LDL-C reduction target achievement compared to AS single-drug treatment in very high-risk patients with high...
These findings confirm earlier reports of escitalopram efficacy in adolescents aged 12-17 years and extend the safety and tolerability data to children with GAD aged 7-11 years.
The blood lipid levels of both control and evolocumab groups stabilized after 1 month.
Patients undergoing vascular surgery show deterioration in their kidney function during the first year, despite statin therapy.
Our findings indicate that statin therapy intensified by ezetimibe may reduce the incidence of heart and blood vessel events within the first 12 months after vascular surgery.
This trial will provide critical, mechanistic evidence on whether the targeted action of L. crispatus can work additively with metformin to heal the intestinal mucosal barrier, arrest systemic endotoxemia, and rescue disrupted gut-brain-endocrine signaling.
Enavogliflozin, added to metformin plus gemigliptin, was well tolerated and as effective as dapagliflozin in the treatment of patients with T2DM.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
